Emergent BioSolutions $150 million at-the-market offering
The shares are listed on the NYSE
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Forbion European Acquisition combination with enGene
We are advising Forbion European Acquisition on its de-SPAC transaction
Merck $6 billion notes offering
The investment-grade notes offering consists of six tranches
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
Olema Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
TransMedics Group $460 million convertible senior notes offering
The convertible senior notes are due 2028
ACELYRIN $621 million IPO
The stock is listed on the Nasdaq Global Select Market
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
Privia Health Group $936 million secondary offering
We advised Privia on the registered secondary offering
DexCom $1.25 billion convertible notes offering and capped call transactions
The 0.375% convertible senior notes are due 2028